On July 18, 2024, Roche announced the positive results of its Phase 1 clinical trial of oral small molecule CT-996 for weight loss. The data showed that the average weight loss of obese subjects without type 2 diabetes after receiving CT-996 treatment for 4 weeks was 6.1% (p<0.001), which was clinically significant. The complete research data is expected to be announced at the upcoming medical conference.
The CT-996-201 trial published this time is a phase I study of multi part, multi cohort, randomized, double-blind, placebo controlled, single and multiple dose increase, which aims to evaluate the safety, tolerance, pharmacokinetics and pharmacodynamics of CT-996 in overweight or obese adults with or without type 2 diabetes.
Analysis showed that after 4 weeks, patients in the CT-996 group lost 7.3% of their body weight, while those in the placebo group lost 1.2%. The difference between the two groups was clinically significant (difference value 6.1%, p<0.001). Pharmacokinetic data supports the once daily oral administration regimen of CT-996. In addition, the research results also indicate that the levels of CT-996 in the blood of subjects were not significantly affected during fasting or after standardized high-fat meals. Therefore, the administration of CT-996 may not require consideration of meal time, making it potentially more flexible to administer. Based on the research data, Roche expects CT-996 to not only be used for blood glucose control and weight loss treatment, but also as an oral weight maintenance therapy for patients after receiving injectable weight loss therapy.
Roche's potential ‘best in class’ small molecule therapy positive clinical results announced
Jul 22, 2024







